Sangamo Therapeutics Inc
NASDAQ:SGMO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.366
1.27
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
128.8m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.8B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Sangamo Therapeutics Inc
Glance View
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Sangamo Therapeutics Inc is -331.3%, which is above its 3-year median of -483.3%.
Over the last 3 years, Sangamo Therapeutics Inc’s Net Margin has decreased from -158.7% to -331.3%. During this period, it reached a low of -2 331.6% on Jun 30, 2024 and a high of -52.8% on Mar 31, 2023.